Meta‐analysis of the hallmark cardiovascular and renal outcome trials addressing the risk for respiratory tract infections with sodium‐glucose co‐transporter‐2 inhibitors: Implications for the COVID‐19 pandemic

Antzeko izenburuak

• Surrogate cardiovascular outcomes with sodium-glucose co-transporter-2 inhibitors in women: An updated meta-analysis
  nork: Patoulias, Dimitrios, et al.
  Argitaratua: (2021)
• Time to assess the effects of sodium–glucose co‐transporter‐2 inhibitors on the ‘forgotten' right ventricle?
  nork: Patoulias, Dimitrios, et al.
  Argitaratua: (2019)
• Sodium–glucose co‐transporter‐2 inhibitors and arterial stiffness: Class effect or drug effect?
  nork: Patoulias, Dimitrios, et al.
  Argitaratua: (2020)
• Prognostic value of arterial stiffness measurements in cardiovascular disease, diabetes, and its complications: The potential role of sodium‐glucose co‐transporter‐2 inhibitors
  nork: Patoulias, Dimitrios, et al.
  Argitaratua: (2020)
• Meta-analysis evaluating the risk of respiratory tract infections and acute respiratory distress syndrome with glucagon-like peptide-1 receptor agonists in cardiovascular outcome trials: Useful implications for the COVID-19 pandemic()
  nork: Patoulias, D., et al.
  Argitaratua: (2022)